

Section 1 Identifying Inform	nation	
1. Given Name (First Name) Michael	2, Sumame (Last Name) Nauck	3. Effective Date (07-August-2008) 02-January-2012
4. Are you the corresponding author?	Yes No	
5. Manuscript Title		

Diagnostic Accuracy of the "Amended" Insulin/Glucose Ratio Derived from Prolonged Fasts for the Biochemical Diagnosis of Insulinomas

6. Manuscript Identifying Number (if you know it)

# A The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration for Publication	
Noney Money to No Paid Your Name of Entity Comments** to You Institution*	
1. Grant	
2. Consulting fee or honorarium	
3. Support for travel to meetings for the study or other purposes	1996 1995 1996 1997
4. Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like	
5. Payment for writing or reviewing  the manuscript	
6. Provision of writing assistance, medicines, equipment, or administrative support.	



The Work Under Consi				
Transfer and the second se				Comments**
7. Other				
* This means money that you	r institution received for your	efforts on this s	tudy,	

\*\* Use this section to provide any needed explanation.

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

**Complete each row by checking "No" or providing the requested information.** If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities outside the submitted work								
					Comments			
1. Board membership					Boehringer Ingelheim, Ingelheim, Germany			
A set dat					Eli Lilly & Co.,			
1. Board membership				1. 1	Indianapolis, Indiana,			
		Norman (n. 1997) Norman (n. 1997)			USA Claure Carliele Klime			
1. Board membership				1	Glaxo, Smith, Kline, Munich, Germany			
					Hoffmann La Roche,			
1. Board membership					Basel, Switzerland			
1. Board membership			71 .	1	Janssen Global			
					Services, LLC, USA	- <u>1996</u> 333344 Talatigina)		
1. Board membership				]	MSD, Munich, Germany			
	· .		i i sha		Novartis Pharma,			
1. Board membership	· .			]	Basel, Switzerland/			
1			÷ .		Nürnberg, Germany			
1. Board membership	· · · · · · · · · · · · · · · · · · ·				Novo Nordisk, Copenhagen, Denmark			
	n en an Alfand Baland. Tha Partier a sao agus				Sanofi-Aventis Pharma,	MARTINE CONTRACTOR		
1. Board membership				<b>1</b> .	Bad Soden/Taunus,			
•	and the second				Germany			



Relevant financial activities outs	ide the s	ubmitted	work		
	No	Money V Faidao You In		Entity ConneerIts	
1. Board membership		$\checkmark$		Takeda, Deerfield, IL, USA	
1. Board membership				Versartis, Sunnyvale, CA, USA	
2. Consultancy				AstraZeneca, Mjölndal, Sweden	
2. Consultancy			<u> </u>	Berlin Chemie AG/ Menarini, Berlin, Germany	
2. Consultancy				Eli Lilly & Co., Indianapolis, Indiana, USA	
2. Consultancy				Hoffman La Roche, Basel, Switzerland	
2. Consultancy		$\checkmark$		MSD, Munich, Germany	
2. Consultancy			:	Novartis Pharma, Basel, Switzerland	
2. Consultancy				Novo Nordisk, Copenhagen, Danmark Sanofi-Aventis Pharma,	
2. Consultancy				Bad Soden/Taunus, Germany	
2. Consultancy				Takeda, Deerfield, IL, USA	
3. Employment	$\checkmark$				
4. Expert testimony					
5. Grants/grants.pending				Berlin Chemie AG/ Menarini, Berlin, Germany	
5. Grants/grants pending			$\checkmark$	Eli Lilly & Co. Indianapolis, Indiana, USA	
5. Grants/grants pending	: :	·	$\checkmark$	MSD Munich, Germany	
5. Grants/grants pending				Novartis Pharma, Basel, Switzerland	



# MEDICAL JOURNAL EDITORS

# **ICMJE Form for Disclosure of Potential Conflicts of Interest**

	Grants/grants pending				AstraZeneca, Södertälje, Sweden Boehringer Ingelheim,
5.	Grants/grants pending	· · ·		$\checkmark$	Ingelheim, Germany
5.	Grants/grants pending			$\checkmark$	GlaxoSmithKline, Philadelphia, USA Lilly Deutschland
5.	Grants/grants pending				Lilly Deutschland GmbH, Bad Homburg, Germany
5.	Grants/grants.pending	·			MataCure Inc, Orangeburg, New York, USA
5.	Grants/grants pending			$\checkmark$	Roche Pharma AG, Grenzach-Wyhlen, Germany
5.	Gramts/grants pending		. 🗆 .	$\checkmark$	Novo Nordisk Pharma GmbH, Mainz, Germany
5.	Grants/grants pending				Tolerx Inc., a delaware Corporation, Cambridge, MA, USA
6.	Payment for lectures including service on speakers bureaus		$\checkmark$		Novo Nordisk, Copenhagen, Danmark
б.	Payment for lectures including service on speakers bureaus				BerlinChemieAG/ Menarini, Berlin, Germany
6.	Payment for lectures including service on speakers bureaus				Lilly Deutschland, Bad Homburg, Germany
б.	Payment for lectures including service on speakers bureaus				MSD, Munich, Germany
	Payment for lectures including service on speakers bureaus				Boehringer Ingelheim, Ingelheim, Germany
б.	Payment for lectures including service on speakers bureaus			<u> </u>	AstraZeneca, Mjölndal, Sweden
б.	Payment for lectures including service on speakers bureaus		$\checkmark$		Roche Pharma AG, Grenzach-Wyhlen, Switzerland
б.	Payment for lectures including service on speakers bureaus				Novartis Pharma, Basel, Switzerland
7.	Payment for manuscript preparation				
8.	Patents (planned, pending or issued)				





9.	Royalties		i i i i i i i i i i i i i i i i i i i		
10.	Payment for development of educational presentations			DIABATE/ Boehringer Ingelheim, Ingelheim, Germany	
10.	Payment for development of educational presentations		$\checkmark$	MSD, Munich, Germany	
10,	Payment for development of educational presentations			Incretin Expert Program/Lilly Deutschland GmbH, Bad Homburg, Germany	
10.	Payment for development of educational presentations			Medscape LLC, NewYork, USA	10,1240.000 (11,120) 10,1240.000 (11,120) 10,1240.0000 (11,120) 10,1240.0000 (11,120) 10,1240.0000 (11,120) 10,1240.0000 (11,120) 10,1240.0000 (11,120) 10,1240.0000 (11,120) 10,1240.0000 (11,120) 10,1240.0000 (11,120) 10,12000 (11,120) 10,12000 (11,120)
11.	Stack/stock options	<b>√</b>			
12.	Travel/accommodations/ meeting expenses unrelated to activities listed**				
13.	Other (err on the side of full disclosure)	✓			

\* This means money that your institution received for your efforts.

\*\* For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

# Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No other relationships/conditions/circumstances that present a potential conflict of interest

Yes, the following relationships/conditions/circumstances are present (explain below):

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Bal Lautohy, 6.7.2012 M. Man



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

#### 1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

#### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



Section 1.	Identifying Infor	mation	
1. Given Name (Fi Juris	irst Name)	2. Surname (Last Name) Meier	3. Effective Date (07-August-2008) 25-September-2012
4. Are you the cor	responding author?	Yes 🖌 No	Corresponding Author's Name Michael Nauck
5. Manuscript Titl Diagnostic accu insulinomas		" insulin/glucose ratio der	ived from prolonged fasts for the biochemical diagnosis of
6. Manuscript Ide	ntifying Number (if you	know it)	

M12-0539

# Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration for Publication								
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**			
1. Grant	$\checkmark$					×		
						ADD		
2. Consulting fee or honorarium	$\checkmark$					×		
						ADD		
3. Support for travel to meetings for the study or other purposes	$\checkmark$					×		
						ADD		
<ol> <li>Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</li> </ol>	$\checkmark$					×		
						ADD		
5. Payment for writing or reviewing the manuscript	$\checkmark$					×		
						ADD		
<ol> <li>Provision of writing assistance, medicines, equipment, or administrative support</li> </ol>	$\checkmark$					×		



The Work Under Consideration for Publication								
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**			
						ADD		
7. Other	$\checkmark$					×		
						ADD		

\* This means money that your institution received for your efforts on this study.

\*\* Use this section to provide any needed explanation.

# Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities outside the submitted work							
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments		
1. Board membership		✓		Astra Zeneca, BMS, Boehringer-Ingelheim, MSD, NovoNordisk, Sanofi-Aventis		×	
						ADD	
2. Consultancy		$\checkmark$		Astra Zeneca, BMS, MSD, NovoNordisk, Sanofi-Aventis		×	
						ADD	
3. Employment	$\checkmark$					×	
						ADD	
4. Expert testimony	$\checkmark$					×	
						ADD	
5. Grants/grants pending			$\checkmark$	NovoNordisk, MSD, Sanofi-Aventis, Eli Lilly, Novartis		×	
						ADD	



Relevant financial activities outside the submitted work								
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments			
6. Payment for lectures including service on speakers bureaus		✓		Astra Zeneca, Berlin- Chemie, Boehringer- Ingelheim, BMS, Eli Lilly, MSD, NovoNordisk, Novartis, Roche, Sanofi-Aventis		×		
						ADD		
7. Payment for manuscript preparation	$\checkmark$					×		
						ADD		
<ol> <li>Patents (planned, pending or issued)</li> </ol>	$\checkmark$					×		
						ADD		
9. Royalties	$\checkmark$					×		
						ADD		
10. Payment for development of educational presentations	$\checkmark$					×		
						ADD		
11. Stock/stock options	$\checkmark$					×		
						ADD		
<ol> <li>Travel/accommodations/ meeting expenses unrelated to activities listed**</li> </ol>	$\checkmark$					×		
						ADD		
13. Other (err on the side of full disclosure)	$\checkmark$					×		
						ADD		

\* This means money that your institution received for your efforts.

\*\* For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

# Section 4. Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

Yes, the following relationships/conditions/circumstances are present (explain below):



At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Hide All Table Rows Checked 'No'



**Evaluation and Feedback** 

Please visit <u>http://www.icmje.org/cgi-bin/feedback</u> to provide feedback on your experience with completing this form.